Advertisement

Topics

Staphylococcus Aureus Infections - Pipeline Review, H1 2015

07:44 EDT 11 Aug 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Staphylococcus Aureus Infections - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-29. This 516-page report is available in PDF from $2000.

Staphylococcus Aureus Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Staphylococcus Aureus Infections - Pipeline Review, H1 2015’, provides an overview of the Staphylococcus Aureus Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Staphylococcus Aureus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Staphylococcus Aureus Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Staphylococcus Aureus Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Staphylococcus Aureus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Staphylococcus Aureus Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Table of Contents
Table of Contents 2
Introduction 7
Staphylococcus Aureus Infections Overview 8
Therapeutics Development 9
Staphylococcus Aureus Infections - Therapeutics under Development by Companies 11
Staphylococcus Aureus Infections - Therapeutics under Investigation by Universities/Institutes 20
Staphylococcus Aureus Infections - Pipeline Products Glance 24
Staphylococcus Aureus Infections - Products under Development by Companies 28
Staphylococcus Aureus Infections - Products under Investigation by Universities/Institutes 41
Staphylococcus Aureus Infections - Companies Involved in Therapeutics Development 47
Staphylococcus Aureus Infections - Therapeutics Assessment 140
Drug Profiles 152
Staphylococcus Aureus Infections - Recent Pipeline Updates 416
Staphylococcus Aureus Infections - Dormant Projects 469
Staphylococcus Aureus Infections - Discontinued Products 482
Staphylococcus Aureus Infections - Product Development Milestones 484
Appendix 491

For more information open Staphylococcus Aureus Infections - Pipeline Review, H1 2015.

SKU: GMDHC6564IDB

Original Article: Staphylococcus Aureus Infections - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Staphylococcus Aureus Infections - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...